|
|
Article: Accentia Announces Investigational New Drug Application for Revimmune Usage in a Pivotal Phase 3 Study of Refractory Multiple Sclerosis.
- Article from:
- Business Wire
- Article date:
- October 8, 2007
CopyrightCOPYRIGHT 2007 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Revolutionary Treatment for Multiple Sclerosis Intended to Eliminate Autoimmunity and Restore Lost Function
TAMPA, Fla. -- Accentia Biopharmaceuticals (NASDAQ: ABPI) announces that it met with the Food and Drug Administration (FDA) on September 26, 2007 for a scheduled pre-Investigational New Drug (pre-IND) meeting on Revimmune[TM]. The FDA has indicated its support for Accentia to submit an IND for a pivotal Phase 3 randomized controlled, multi-center clinical trial of Revimmune, the company's potential therapeutic for refractory, relapsing-remitting Multiple Sclerosis (MS). The FDA indicated that they support the proposed submission from Accentia and that they ...
Related newspaper, magazine, and journal articles:
|
|
Article: Findings from Johns Hopkins University broaden ...
Immunotherapy Weekly;
May 27, 2009 ;
700+ words
... ... colleagues, Johns Hopkins University ... disability in multiple sclerosis and have implications ... dysfunction in multiple sclerosis and column ... Zackowski, Johns Hopkins University ... Resonance, Multiple Sclerosis, Neuroimmunology ...
|
|